BridgeBio Pharma, Inc. (BBIO) Earnings & Analysis

Latest quarter

BridgeBio reported Q3 FY2026 revenue of $353.2 million, above the $296.6 million consensus and up from $120.7 million a year earlier. Its adjusted loss was −$0.42 per share, compared with the consensus estimate of −$0.60. On a diluted basis, the company reported a loss of −$0.31 per share, versus −$0.95 a year earlier.

The filing attributed the revenue increase in part to Attruby’s commercial expansion and patient demand. U.S. net product revenue from Attruby was $253.2 million, while license revenue included a $75.0 million one-time Beyonttra sales milestone. BridgeBio also reported $20.5 million in royalty revenue, primarily from Beyonttra sales in Europe and Japan.

BridgeBio’s gross margin was 94.2%, compared with 94.6% a year earlier, while its operating margin moved to −3.30% from −120.3%. The company reported free cash flow of −$44.5 million, compared with −$112.4 million a year earlier, and held $1.5 billion in cash, cash equivalents and marketable securities at quarter-end.

Adjusted EPS is the figure the consensus estimates, not the GAAP EPS above.

What management said on the call

CEO Neil Kumar said Attruby’s growth was predominantly coming from patients starting treatment in the first-line setting. He said BridgeBio planned to broaden its outreach to physicians who had not yet prescribed the drug, including lower-volume and non-cardiology specialists. Chief Business Officer Chinmay Shukla said expanding that prescriber base could be a source of future U.S. growth.

Chief Commercial Officer Matthew Outten said Attruby’s gross-to-net pricing had remained stable and that the number of new prescribers using it first-line continued to grow each quarter. Asked about a proposed change affecting drug pricing, he said its final form was uncertain and that it would affect Part B medicines, not Part D medicines such as Attruby.

Kumar said Beyonttra was the leading brand in Europe. He also said BridgeBio could not yet quantify Attruby’s new-prescription share on the call because it had not seen a competitor’s quarterly figures. CFO Thomas Trimarchi attributed the improvement in the operating result to Attruby revenue, Beyonttra royalties and the one-time milestone, partly offset by increased operating expenses. He said launch-related expenses had been affected by timing and would catch up in the fourth quarter.

On the pipeline, Kumar said BridgeBio had identified patients for BBP-418 and was preparing for a potential launch in limb-girdle muscular dystrophy, subject to approval. Neuromuscular franchise leader Anna Wade said the company expected to reach the identified patient pool by the third year of launch and would provide more quantitative launch metrics later.

Asked about a citizen petition concerning infigratinib, program leader Justin To said BridgeBio did not expect it to affect the review timeline or label. Kumar said the company had also started a registrational study of encaleret in chronic hypoparathyroidism, beyond its application for ADH1.

Guidance

BridgeBio expects Attruby revenue to increase sequentially by $25.0 million to $30.0 million in Q4 FY2026. Trimarchi said operating expenses would catch up in the fourth quarter, followed by more modest steady growth and improvement in the operating line in the following year and beyond.